Agios Pharmaceuticals, Inc. (AGIO) Stock Price

AGIOStock

$31.32−24.57%52W

Market Cap$1.87B

P/E2.61x

PEG Ratio—

Div yield—

Beta0.62

AGIO Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-15.85%

Price vs S&P 500 (4W)-6.42%

VGM Score61.05

P/E Ratio (Annual)2.61x

Book Value / Share (Quarterly)$17.21

P/TBV (Annual)1.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)55.97%

Cash Flow / Share (Quarterly)$-6.13

Price vs S&P 500 (YTD)3.14%

Gross Margin (TTM)91.99%

Net Profit Margin (TTM)-418.24%

EPS (TTM)$-7.01

10-Day Avg Trading Volume1.24M

EPS Excl Extra (TTM)$-7.01

Revenue Growth (5Y)4.67%

EPS (Annual)$-7.12

ROI (Annual)-34.60%

Gross Margin (Annual)88.26%

Net Profit Margin (5Y Avg)-445.03%

Cash / Share (Quarterly)$10.36

Revenue Growth QoQ (YoY)259.25%

P/E Normalized (Annual)2.61x

ROA (Last FY)-31.82%

Revenue Growth TTM (YoY)140.58%

EBITD / Share (TTM)$-7.73

ROE (5Y Avg)13.77%

Operating Margin (TTM)-466.78%

Cash Flow / Share (Annual)$-6.46

P/B Ratio1.82x

P/B Ratio (Quarterly)2.15x

Net Income / Employee (Annual)$-765,800

EV / Revenue (TTM)18.00x

ROA (TTM)-33.06%

EV / EBITDA (TTM)2.80x

EPS Incl Extra (Annual)$-7.12

Current Ratio (Annual)11.46x

Quick Ratio (Quarterly)9.14x

3-Month Avg Trading Volume1.14M

52-Week Price Return-24.57%

Revenue / Employee (TTM)$182,400

Tangible BV / Share (Quarterly)$15.87

P/S Ratio (Annual)34.61x

Asset Turnover (Annual)0.04x

52-Week High$46.00

Operating Margin (5Y Avg)-532.96%

EPS Excl Extra (Annual)$-7.12

CapEx CAGR (5Y)-21.96%

Tangible BV CAGR (5Y)24.00%

26-Week Price Return-5.95%

Quick Ratio (Annual)10.52x

13-Week Price Return-20.93%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.22x

Enterprise Value$1.77B

Revenue / Share Growth (5Y)0.19%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)28.77%

Revenue / Employee (Annual)$100,200

Inventory Turnover (Annual)0.21x

Pretax Margin (Annual)-765.89%

Cash / Share (Annual)$14.62

3-Month Return Std Dev41.46%

Gross Margin (5Y Avg)90.54%

Net Income / Employee (TTM)$-763,100

ROE (Last FY)-34.60%

EPS Basic Excl Extra (Annual)$-7.12

Receivables Turnover (TTM)6.74x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-7.01

Receivables Turnover (Annual)7.36x

ROI (TTM)-35.67%

P/S Ratio (TTM)19.01x

Pretax Margin (5Y Avg)-421.16%

Revenue / Share (Annual)$0.93

Tangible BV / Share (Annual)$20.00

Price vs S&P 500 (52W)-40.10%

Year-to-Date Return15.06%

5-Day Price Return1.62%

EPS Normalized (Annual)$-7.12

ROA (5Y Avg)12.81%

Net Profit Margin (Annual)-764.01%

Month-to-Date Return-5.80%

Cash Flow / Share (TTM)$-3.84

EBITD / Share (Annual)$-8.05

EPS Growth (3Y)-24.03%

Operating Margin (Annual)-873.87%

ROI (5Y Avg)13.76%

EPS Basic Excl Extra (TTM)$-7.01

P/TBV (Quarterly)1.41x

P/B Ratio (Annual)1.33x

Inventory Turnover (TTM)0.26x

Pretax Margin (TTM)-419.27%

Book Value / Share (Annual)$20.41

Price vs S&P 500 (13W)-23.61%

Beta0.62x

P/FCF (Annual)65.29x

Revenue / Share (TTM)$1.65

ROE (TTM)-35.67%

52-Week Low$22.24

vGradeC

gGradeB

mGradeC

vgmGradeB

AGIO Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	-$1.67	-$1.69	-1.50%(-$0.02)
Q1 2026	Apr 29, 2026	-$1.79	-$1.69	+5.66%(+$0.10)
Q4 2025	Feb 12, 2026	-$1.95	-$1.85	+4.88%(+$0.09)
Q3 2025	Oct 30, 2025	-$1.90	-$1.78	+6.53%(+$0.12)
Q2 2025	Jul 31, 2025	-$1.75	-$1.93	-10.03%(-$0.18)

AGIO Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.06

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AGIOAgios Pharmaceuticals, Inc.	C	B	C	19.0x	140.6%	92.0%	—	$31.32
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals develops small-molecule medicines for rare hematologic diseases through cellular metabolism pathways. Its lead product, Pyrukynd (mitapivat), is a pyruvate kinase activator for hemolytic anemias, with additional pipeline candidates targeting sickle cell disease and myelodysplastic syndrome-associated anemia. The company addresses significant unmet medical needs in rare blood disorders.

AGIO Next Earnings Report

Report dateNov 5, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$1.22

Revenue estimate$51.90M

Also reporting on Nov 5, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AGIO Insider Transactions

SellAug 4, 2026
GHEUENS SARAH
Officer
Shares: 30,000Value: $914,400

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for August 2026

Companies in Related Industries

MTXMinerals Technologies IncIndustrial Chemicals
STDNStandard Nuclear, Inc.Industrial Chemicals
TRLVTrulieve Cannabis Corp.Pharmaceutical Preparations
CCThe Chemours CompanyChemicals
RXRXRecursion Pharmaceuticals, Inc. Class A Common StockBiological Products
NVAXNovavax IncBiological Products
ALVOAlvotech Ordinary SharesBiological Products
OLNOlin Corp.Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$22.24

High$46.00